By Karen Roman Biopharmaceutical company Medera Inc. said it completed patient enrollment for Cohort B of its clinical trial evaluating SRD-002 gene therapy for heart failure with preserved ejection fraction (HFpEF). This milestone allows Medera to advance to Phase 2b...

By Karen Roman SkylineDx said it published new peer-reviewed data where its Merlin CP-GEP Test outperforms the competition and current standards of care for identifying melanoma risk using molecular testing. In response to a competitor’s study comparing its own test...

By Karen Roman Sequana Medical NV (BRU: SEQUA.BR) said it successfully implanted the alfapump device for treatment of recurrent or refractory ascites due to liver cirrhosis in two patients at the University of Pennsylvania. The alfapump is the first FDA-approved...

By Daniella Parra March Bio is developing MB-105, a first-in-class autologous CD5-targeted CAR-T cell therapy for relapsed/refractory T-cell lymphoma and other CD5-positive hematologic malignancies, they said. The company said the therapy employs a proprietary CAR design that enables selective targeting of...

Exec Edge hosted a fireside chat on Dec. 8 from the Nasdaq Marketsite with Chris Searles, co-founder and Chief Executive Officer, and Trevor Smith, co-founder and Chief Technology Officer of DxCheck. The in-person interview was joined by Editor-in-Chief John Jannarone and...

IPO Edge hosted a fireside chat on Dec. 8 from the Nasdaq Marketsite with Christer Rosen, Chairman and Chief Executive Officer, and Alison Silva, President and Chief Business Officer of Jupiter Neurosciences, Inc. (Nasdaq: JUNS). The in-person interview was joined by...

By Daniella Parra ReAlta Life Sciences’ Pegtarazimod demonstrated significant clinical improvement and reduction in inflammatory markers in patients with lower gastrointestinal aGvHD, the company said. Clinical MAGIC stage improvement observed for 6 of 6 patients with steroid-refractory aGvHD, with 4...

By Karen Roman March Biosciences said it appointed Gurpreet Ratra, Ph.D., as Chief Business Officer. Dr. Ratra has more than 25 years of experience in the life science industry including cell and gene therapy, as well as equity research leadership, the...

By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it is presenting new research at the 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference, being held on December 1-4, 2025, in San Diego, California. Acumen and JCR Pharmaceuticals are...

By Karen Roman ReAlta Life Sciences, Inc. announced the designation of Howard Berman, Ph.D., as Executive Chairman of its Board of Directors, effective immediately. “His proven track record in advancing innovative immunology-based therapies and creating value, positions ReAlta for disciplined growth...